pulse2.com
Cure8 news brief
Why This Matters
Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.
A Phase 2 study of RXC008 is planned, and a DDR inhibitor IND is targeted for 2027, so this could affect future treatment development and trial opportunities.
Who Should Pay Attention
Adult patients with Crohn’s disease (especially those with fibrostenotic/stricturing disease), clinicians treating IBD, clinical researchers in fibrosis and IBD, and patient advocates tracking therapeutic pipelines.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
Biotech deal news: Skye Bioscience is combining with Redx to form Fibrx Therapeutics and pivot toward anti-fibrotic drug development for fibrostenotic Crohn’s disease. The lead clinical asset is RXC008, an oral GI‑restricted pan‑ROCK inhibitor with an open U.S. IND and Fast Track designation that is ready for Phase 2 (expected H2 2028).
The company also inherits a preclinical DDR inhibitor portfolio targeting fibrosis with a planned 2027 IND, plus other ROCK inhibitors positioned for partnering. The report is a financing and pipeline/strategy summary rather than clinical results.
It outlines ownership, financing (~$125M), transaction timing (expected close Q4 2026), and contingent value rights for prior Skye shareholders tied to the discontinued obesity asset nimacimab.
The article quotes company leadership about targeting fibrostenotic Crohn’s (a stricture/fibrosis indication) and emphasizes there are currently no approved anti‑fibrotic medical therapies for stricturing disease beyond surgery.
This brief is grounded in the source article text and company statements in the news report; it does not summarize any clinical trial outcomes or peer‑reviewed data.
Keep In Mind
This is a business/financing report and pipeline summary rather than clinical data. RXC008 has regulatory designations (open IND, Fast Track) but reported timelines and financing plans are company statements and subject to change. No clinical efficacy or safety results are presented in this article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationpulse2.com
AuthorsAmit Chowdhry
Indexed viaGoogle News
Source typeWeb article
PublishedAug 17, 2026, 5:02 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Shattuck Labs Incurs Higher Q2 Loss; To Advance SL-325 In Phase 2b For Crohn's Disease In Q3 '26
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
Palisade Bio (NASDAQ: PALI) boosts PALI-2108 to Phase 2 with $125M cash runway
This filing reports that PALI‑2108, an investigational oral PDE4 prodrug for IBD, showed encouraging Phase 1 signals and is moving into Phase 2 trials — a step toward more definitive efficacy data. The company also...
Graham Heap Joins cAMPfield as R&D President to Advance Prifemilast Phase 2 Program
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...